The new platform is a part of Heta-based QSP modeling infrastructure
[Moscow – 11.08.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, now presents HetaSimulator. It is a part of Heta project that embraces three components. HetaSimulator is an OpenSource simulation and parameters estimation platform for the Heta modeling language.
Now IRT gets significant update and a portion of new data
[Moscow – 22.07.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches Immune Response Template (IRT) version 3.5.0.
[Moscow – 19.05.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches the new version (0.3.0) of its SbmlViewer open project. Generally, SbmlViewer is a tool for fast and easy reading and transformation of biological models written in SBML format.
InSysBio presents the major updates of Heta compiler. Heta compiler is a software tool for development of QSP modeling platforms. In fact, its core option is the compilation of Heta-based platforms. Its functionality has been significantly elaborated and now Heta compiler has become even more useful and functional.
IRT gets new data and recalculated parameters
[Moscow – 30.03.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches Immune Response Template (IRT) version 3.4.0. IRT represents a Quantitative Systems Pharmacology (QSP) platform of immune system simultaneously being a tool for development of models related to immune system. IRT is based on two main components.
[Moscow – 15.02.2021] Oleg Demin Jr, Head of Oncology and Immuno-Oncology at InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, has talked to startup.info, a global innovation ecosystem magazine. The interview in frames of the series "INNOVATORS VS COVID-19" covers the application of system-pharmacology modeling to different stages of drug research and development and InSysBio's current development in the context of the pandemic.
We use cookies (and other similar technologies) to collect data to improve your experience on our site.
By using our website, you agree to data collection as described in our website’s data collection policy.